Oncology has a higher rate of attrition in clinical development than most other therapeutic areas. Lengauer and colleagues discuss the factors responsible, and suggest strategies to improve the chances of short-term success in the development of novel anticancer drugs.
- Alexander Kamb
- Susan Wee
- Christoph Lengauer